Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Marriott International Inc (MAR) Price & Performance

Amylx Pharmaceuticals IncTrade
Marriott International Inc Trade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Marriott International Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Marriott International Inc trades at $349.5 (market cap $90.86B). The key difference: Marriott International Inc is far larger — about 35.9× Amylx Pharmaceuticals Inc's market cap, and Marriott International Inc pays a 0.84% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXMAR
Market Cap
$2.53B$90.86B
Sector
HealthConsumer Cyclical
52-Week High
$24.19$402.54
52-Week Low
$7.82$257.97
Enterprise Value
$2.28B$108.17B
Dividend Yield
0.84%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Marriott International Inc

Marriott International (MAR) trades at $353.91, down 1.6% in the last 24 hours, with a bearish technical signal. The stock shows strong profitability with a net income margin of 9.62% and ROE of 1,446.77%, but faces high valuation ratios like a P/E of 36.64. Recent Q2 2026 earnings beat estimates at $3.19 per share, and the company raised its 2026 outlook, though revenue missed expectations. A quarterly dividend of $0.73 per share was declared, payable on June 30, 2026.

The outlook is mixed: robust fee growth and a record pipeline support upside, but elevated debt and premium valuation pose risks. Analysts are generally positive with a consensus price target of $387.31, though near-term volatility may persist due to macroeconomic headwinds and regional weaknesses in the Middle East.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Marriott International Inc

Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.

Read more on MAR